Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulrodemstat + nivolumab in advanced SCLC and sqNSCLC
NCT04350463Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of pulrodemstat in small cell lung cancer (SCLC), squamous cell carcinoma of the lung (SCCL), sponsored by Celgene Corporation. Started Jul 2020; status: completed.
02
Drugs
pulrodemstat
03
Conditions
small cell lung cancer (SCLC)squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT04350463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350463.